Ellen J. Sass

1.0k total citations
17 papers, 874 citations indexed

About

Ellen J. Sass is a scholar working on Molecular Biology, Genetics and Hematology. According to data from OpenAlex, Ellen J. Sass has authored 17 papers receiving a total of 874 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 10 papers in Genetics and 3 papers in Hematology. Recurrent topics in Ellen J. Sass's work include Chronic Lymphocytic Leukemia Research (9 papers), Ubiquitin and proteasome pathways (5 papers) and Neuroscience and Neuropharmacology Research (2 papers). Ellen J. Sass is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Ubiquitin and proteasome pathways (5 papers) and Neuroscience and Neuropharmacology Research (2 papers). Ellen J. Sass collaborates with scholars based in United States, Italy and Vietnam. Ellen J. Sass's co-authors include T.A. Rooney, Ap Thomas, Andrew P. Thomas, Andrew P. Thomas, Dominique Renard, David Lucas, Xiaoli Zhang, David Jarjoura, A. Douglas Kinghorn and John C. Byrd and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Ellen J. Sass

16 papers receiving 861 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ellen J. Sass United States 9 663 239 104 97 86 17 874
Katalin Pászty Hungary 24 818 1.2× 169 0.7× 93 0.9× 174 1.8× 232 2.7× 41 1.1k
Malay K. Raychowdhury United States 16 616 0.9× 122 0.5× 45 0.4× 111 1.1× 104 1.2× 20 1.0k
Giovanni Monaco Belgium 18 939 1.4× 191 0.8× 56 0.5× 122 1.3× 295 3.4× 30 1.2k
Alison D. Short United States 12 838 1.3× 244 1.0× 67 0.6× 150 1.5× 217 2.5× 18 1.1k
Nadine Henke Germany 15 656 1.0× 251 1.1× 41 0.4× 116 1.2× 114 1.3× 15 1.2k
A H Tashjian United States 13 476 0.7× 170 0.7× 78 0.8× 57 0.6× 107 1.2× 15 733
Yosuke Tojyo Japan 18 647 1.0× 207 0.9× 64 0.6× 147 1.5× 192 2.2× 67 904
Janet E. Merritt United Kingdom 12 514 0.8× 240 1.0× 55 0.5× 67 0.7× 104 1.2× 24 785
Christiane Klec Austria 23 966 1.5× 134 0.6× 160 1.5× 48 0.5× 91 1.1× 34 1.3k
Bahman Aghdasi United States 9 786 1.2× 151 0.6× 35 0.3× 43 0.4× 95 1.1× 9 927

Countries citing papers authored by Ellen J. Sass

Since Specialization
Citations

This map shows the geographic impact of Ellen J. Sass's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen J. Sass with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen J. Sass more than expected).

Fields of papers citing papers by Ellen J. Sass

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen J. Sass. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen J. Sass. The network helps show where Ellen J. Sass may publish in the future.

Co-authorship network of co-authors of Ellen J. Sass

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen J. Sass. A scholar is included among the top collaborators of Ellen J. Sass based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen J. Sass. Ellen J. Sass is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Rogers, Kerry A., Eric McLaughlin, Lai Wei, et al.. (2023). Initial Results of a Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL. Blood. 142(Supplement 1). 1899–1899. 1 indexed citations
2.
Rogers, Kerry A., Lynne V. Abruzzo, Seema A. Bhat, et al.. (2022). Four-year follow-up from a phase 2 study of obinutuzumab, ibrutinib, and venetoclax in CLL.. Journal of Clinical Oncology. 40(16_suppl). 7540–7540. 3 indexed citations
3.
Elgamal, Sara, Michael Gulrajani, Jean Cheung, et al.. (2022). Elucidating the Mechanism of Action (MOA) of Navtemadlin, an MDM2 Inhibitor, and Its Synergy with Gilteritinib in Myeloid Malignancies. Blood. 140(Supplement 1). 5936–5938. 1 indexed citations
4.
Elgamal, Sara, Emanuele Cocucci, Ellen J. Sass, et al.. (2021). Optimizing extracellular vesicles’ isolation from chronic lymphocytic leukemia patient plasma and cell line supernatant. JCI Insight. 6(15). 4 indexed citations
5.
Lehman, Amy, Bonnie K. Harrington, Fabienne Lucas, et al.. (2017). BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia. Blood Advances. 1(24). 2147–2160. 3 indexed citations
6.
Lehman, Amy M., Ellen J. Sass, Minh Tran, et al.. (2016). BRAFV600E Accelerates Disease Progression and Increases Immune Suppression in a Mouse Model of B-Cell Leukemia. Blood. 128(22). 1206–1206.
7.
Ren, Yulin, Wei-Lun Chen, Daniel D. Lantvit, et al.. (2016). Cardiac Glycoside Constituents of Streblus asper with Potential Antineoplastic Activity. Journal of Natural Products. 80(3). 648–658. 49 indexed citations
8.
Awan, Farrukh T., Joseph M. Flynn, Jeffrey A. Jones, et al.. (2015). Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia & lymphoma. 56(10). 2834–2840. 12 indexed citations
9.
Lozanski, Gerard, Amy Lehman, Ellen J. Sass, et al.. (2015). BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation. Leukemia Research. 39(11). 1270–1277. 6 indexed citations
10.
Gupta, Sneha, Erin Hertlein, Yanhui Lu, et al.. (2013). The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells. Clinical Cancer Research. 19(9). 2406–2419. 31 indexed citations
11.
Li, Pan, Ellen J. Sass, Sneha Gupta, et al.. (2012). Potentiating Effect of the Flavonolignan (‐)‐Hydnocarpin in Combination with Vincristine in a Sensitive and P‐gp‐Expressing Acute Lymphoblastic Leukemia Cell Line. Phytotherapy Research. 27(11). 1735–1738. 15 indexed citations
12.
Gupta, Sneha, Ellen J. Sass, Melanie E. Davis, et al.. (2011). Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells. The AAPS Journal. 13(3). 357–64. 63 indexed citations
13.
14.
Hertlein, Erin, Georgia Triantafillou, Ellen J. Sass, et al.. (2010). Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood. 116(14). 2554–2558. 34 indexed citations
15.
Rooney, T.A., Dominique Renard, Ellen J. Sass, & Andrew P. Thomas. (1991). Oscillatory cytosolic calcium waves independent of stimulated inositol 1,4,5-trisphosphate formation in hepatocytes. Journal of Biological Chemistry. 266(19). 12272–12282. 128 indexed citations
16.
Rooney, T.A., Ellen J. Sass, & Andrew P. Thomas. (1990). Agonist-induced cytosolic calcium oscillations originate from a specific locus in single hepatocytes.. Journal of Biological Chemistry. 265(18). 10792–10796. 199 indexed citations
17.
Rooney, T.A., Ellen J. Sass, & Ap Thomas. (1989). Characterization of Cytosolic Calcium Oscillations Induced by Phenylephrine and Vasopressin in Single Fura-2-loaded Hepatocytes. Journal of Biological Chemistry. 264(29). 17131–17141. 323 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katalin Pászty Breakdown of academic impact, for papers by Malay K. Raychowdhury Breakdown of academic impact, for papers by Giovanni Monaco Breakdown of academic impact, for papers by Alison D. Short Breakdown of academic impact, for papers by Nadine Henke Breakdown of academic impact, for papers by A H Tashjian Breakdown of academic impact, for papers by Yosuke Tojyo Breakdown of academic impact, for papers by Janet E. Merritt Breakdown of academic impact, for papers by Christiane Klec Breakdown of academic impact, for papers by Bahman Aghdasi
Rankless by CCL
2026